Brentie has posted a link to a post whose author believes

New Post Public Reply Private Reply Replies (3) Message Board
KenChowder brentie #163255
822
Brentie has posted a link to a post whose author believes that one one slot has been filled in the TNBC EAP in Salem, Oregon.  This must be the result of too little information.  So I took it upon myself to write to Oregon breast=cancer organizations, including Breast Friends, Pink Sistahs, and the Yew Club.  (Haven't been able to find a good email address for the OHSU Knight Breast Cancer Institute, but they might already be involved.)  Here's what I wrote, in case anyone wants to use it as a template in writing Breast-cancer organization anywhere.
(I realize some might think such letter-writing untoward.  They might be right.  But it might help, too.)

Quote:
I'm a former Portlander. I had a very dear friend who passed from triple-negative breast cancer. I'm writing to see if you would post information to the Yew Club about a Salem TNBC trial -- or disseminate the information in whatever way you can. I wrote to Breast Friends at the mail address, but not sure if that will reach a genuine person. (I'm not on Insta! Old person alert!)

I'm writing about a TNBC trial for a drug called Leronlimab, a monocolonal antibody. The trial is part of an expanded access program.

Here are some crucial facts:

1) The trial involves giving the patient Leronlimab; in the great majority of cases, this elevates PD-L1, which makes a checkpoint inhibitor like Keytruda a viable treatment option. In an earlier trial, six years ago, exactly five women were given this combination. All five had failed at least three earlier courses of treatment, and all five survive today, six years later. Four have no evidence of disease. So it's a good chance.

2) The trial is free of charge for the Leronlimab. Once the PD-L1 is sufficiently elevated, the patient's primary oncologist can then add an ICI, and patient insurance will pay for it.

3) The trial is being held in Salem.

4) Leronlimab has been given to over 1600 patients, most of them with crashed immunity systems, and yet there have been zero serious adverse events -- side effects. It is far safer than aspirin. It is not another round of grueling chemotherapy.

Patients must have metastatic or locally advanced TNBC and not have adequate treatment options available to them.

The way it works is this: most TNBC tumors are "cold" tumors, with few active immune cells. Leronlimab alters the tumor microenvironment so that it becomes "hot" -- and thus treatable. Leronlimab significantly increases PD-L1 expression on tumor cells in traditionally cold, resistant cancers.This effectively "ignites" the tumor, rendering it highly susceptible to Immune Checkpoint Inhibitors (like Keytruda) that previously would not work. When the PD-L1 is elevated (via Leronlimab), an ICI becomes the standard-of-care treatment, and works well.

Leronlimab blocks/occupies the CCR5 receptor, which is ubiquitous in the MOA of most solid-tumor cancers. Leronlimab has also been shown to drastically limit the traveling cancer cells that cause metastases.

Twenty slots are available for the trial, which has been funded by an anonymous (and thus mysterious) donor.

Here's contact info for the trial, from the clinicaltrials.gov site:

Study Contact

Name: Janet Brockus

Phone Number: 360-980-8524

Email: jbrockus@cytodyn.com

Study Contact Backup

Name: Joe Meidling

Phone Number: 360-980-8524

Email: jmeidling@cytodyn.com

I hope you can use this info to help some women in your network! This is a lethal disease that can literally be cured.

Yours with best -- Ken Glantz p.s. I can provide more info about Leronlimab if it helps. Here are some links for info and reference:

Clinicaltrials.gov link to the trial above:

https://clinicaltrials.gov/study/NCT07536815?...amp;rank=3

Leronlimab earlier trial results vs. msTNBC -- abstract published by Am. Association of Cancer Research, and poster presented there

> Abstract Feb. 2026

> https://aacrjournals.org/cancerimmunolres/art...-with-long

Poster

>> https://d1io3yog0oux5.cloudfront.net/_976f96f...evised.pdf

April 2026 abstract to AACR meeting:

> https://www.abstractsonline.com/pp8/#!/21436/...ation/9742

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 398

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring CRH Stock Performance Over Five Years and Beyond

Updated Category News Views 152

Understanding CRH's Impressive Growth CRH has displayed a remarkable performance in the stock market over the last five years, outshining many of its competitors with a 10.67% annualized return. This impressive growth translates to an average annual return of 23.49% for investors. Currently, CRH boasts a market capitalization of approximately $73.09 billion, making it a...

Continue Reading
Coordinated Care's Health Tour Expands Access Across WA

Updated Category News Views 78

A Grassroots Push for Health Equity Coordinated Care, a subsidiary of Centene Corporation, is hitting the road in Washington state. This isn't about just another healthcare campaign—you’ve got two vans, 'SeeMore' and 'Flossy', bringing essential vision and dental screenings right up to the folks who need them most. Taking Healthcare Directly to Communities Let's be...

Continue Reading
Italy's Antitrust Agency Investigates Snam-Edison Deal

Updated Category News Views 229

Investigation into the Snam and Edison Gas Storage Deal Italy's antitrust agency has recently initiated an investigation concerning the transaction between Snam and Edison involving Edison's gas storage unit. This move reflects the agency's commitment to maintaining healthy competition within the energy sector. Concerns Over Market Competition The Antitrust Authority,...

Continue Reading
Truist Financial Corporation's Quarterly Performance Insights

Updated Category News Views 240

Truist Financial's Results and Earnings Overview Truist Financial Corporation (TFC) announced its latest quarterly results, showcasing a robust financial performance that illustrates the company’s strategic focus on growth and stability. This release reflects the commitment of Truist to enhance the lives of its clients and communities by providing comprehensive...

Continue Reading
Investigation Into Possible Securities Fraud at UnitedHealth Group

Updated Category News Views 350

UnitedHealth Group Under Scrutiny for Securities Claims Ademi & Fruchter LLP has launched an investigation into potential securities fraud claims against UnitedHealth Group Incorporated (NYSE: UNH). This inquiry arises following inaccurate statements made by the company regarding its operational performance and future outlook. Investors and analysts alike express serious...

Continue Reading